These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 22025647)

  • 21. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
    Akarte AS; Srinivasan BP; Gandhi S
    J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
    D'Alessio DA; Denney AM; Hermiller LM; Prigeon RL; Martin JM; Tharp WG; Saylan ML; He Y; Dunning BE; Foley JE; Pratley RE
    J Clin Endocrinol Metab; 2009 Jan; 94(1):81-8. PubMed ID: 18957505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
    Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
    J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
    Ahrén B; Landin-Olsson M; Jansson PA; Svensson M; Holmes D; Schweizer A
    J Clin Endocrinol Metab; 2004 May; 89(5):2078-84. PubMed ID: 15126524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
    Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
    Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy.
    Ren X; Liu G; Wang Y; Zhang W; Xue F; Li R; Yu W
    Pharmacology; 2017; 100(1-2):1-13. PubMed ID: 28329747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Pharmacology; 2009; 83(3):177-87. PubMed ID: 19176982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.
    Fujita H; Taniai H; Murayama H; Ohshiro H; Hayashi H; Sato S; Kikuchi N; Komatsu T; Komatsu K; Komatsu K; Narita T; Yamada Y
    Endocr J; 2014; 61(2):159-66. PubMed ID: 24225429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
    Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
    Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
    Rieg T; Gerasimova M; Murray F; Masuda T; Tang T; Rose M; Drucker DJ; Vallon V
    Am J Physiol Renal Physiol; 2012 Oct; 303(7):F963-71. PubMed ID: 22832924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
    Gangadharan Komala M; Gross S; Zaky A; Pollock C; Panchapakesan U
    Nephrology (Carlton); 2016 May; 21(5):423-31. PubMed ID: 26375854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats.
    Sufiun A; Rafiq K; Fujisawa Y; Rahman A; Mori H; Nakano D; Kobori H; Ohmori K; Masaki T; Kohno M; Nishiyama A
    Hypertens Res; 2015 Apr; 38(4):237-43. PubMed ID: 25588850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
    Reichetzeder C; von Websky K; Tsuprykov O; Mohagheghi Samarin A; Falke LG; Dwi Putra SE; Hasan AA; Antonenko V; Curato C; Rippmann J; Klein T; Hocher B
    Br J Pharmacol; 2017 Jul; 174(14):2273-2286. PubMed ID: 28423178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
    Kalra S
    J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
    Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
    Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.
    Sudre B; Broqua P; White RB; Ashworth D; Evans DM; Haigh R; Junien JL; Aubert ML
    Diabetes; 2002 May; 51(5):1461-9. PubMed ID: 11978643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1α.
    Connelly KA; Advani A; Zhang Y; Advani SL; Kabir G; Abadeh A; Desjardins JF; Mitchell M; Thai K; Gilbert RE
    J Diabetes; 2016 Jan; 8(1):63-75. PubMed ID: 25565455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.